Bicycle Health: Clinicians Prepare for 7-OH Patient Surge as Federal Schedule I Order Approaches

Why it matters

As the DEA order approaches, clinicians across all 50 states face a new category of opioid-dependent patient: people who believed they were using a legal supplement and now face both supply disruption and federally criminal possession. Treatment providers report growing demand for buprenorphine initiation specifically from 7-OH users.

The big picture

Bicycle Health, a telehealth opioid use disorder treatment provider, assembled a detailed regulatory and clinical reference updated as of July 21, 2026, documenting both the current legal status of 7-OH and the clinical pathway for dependent users. The analysis draws on the Federal Register notices, DEA press materials, and HHS documentation, while providing the treatment context that government sources omit. The 0.05% threshold was chosen to sit between the trace levels in natural kratom leaf (0.003–0.04%) and the manufactured concentrations in commercial products (22–75 mg/g or higher).

Key findings

• As of July 21, 2026, 7-OH above the 0.05% threshold is not yet federally scheduled; the DEA order cannot publish before August 5, 2026
• Nine states ban kratom outright as of July 2026; several others (Florida, Ohio, Virginia, Colorado, South Carolina) restrict concentrated 7-OH while keeping leaf legal
• Virginia's July 1, 2026 law banned concentrated 7-OH at retail while keeping natural kratom leaf legal for adults 21+, requiring products in locked cases with warning labels
• Rhode Island became the first state to reverse its kratom ban, doing so effective April 1, 2026
• Buprenorphine/naloxone is FDA-approved for opioid use disorder and effective for 7-OH dependence, available via telehealth in most states
• The HHS public comment period on the 0.05% threshold closed July 31, 2026

What they say

The American Kratom Association stated on July 1 that the DEA action "confirms what the AKA has repeatedly warned: chemically manipulated 7-OH opioid products are not natural kratom leaf products."

Bottom line

The regulatory line between botanical kratom and concentrated 7-OH is now a clinical frontline: providers should expect an influx of patients seeking buprenorphine treatment for 7-OH dependence as federal scheduling approaches.